Search

Your search keyword '"Kim, Tae Hoon"' showing total 352 results
Start Over Author "Kim, Tae Hoon" Publisher elsevier b.v.
352 results on '"Kim, Tae Hoon"'

6. Bimetallic NiO/NiFe2O4 heterostructures with interfacial effects for boosting electrochemical water splitting applications

Author

Jesudass, Sebastian Cyril, Surendran, Subramani, Kim, Joon Young, Shanmugapriya, Sathyanarayanan, Moon, Dae Jun, Janani, Gnanaprakasam, Veeramani, Krishnan, Mahadik, Shivraj, Choi, Jinuk, Jung, Pildo, Kim, Il Goo, Park, Hyunjung, Han, Hyun Soo, Choi, Heechae, Kwon, Gibum, Heo, Jaeyeong, Hong, Kootak, Kim, Tae-Hoon, Park, Yong Il, and Sim, Uk

Published
2024
Full Text
View/download PDF

25. Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial.

Author

Lee, Sang-Hyup, Lee, Seung-Jun, Heo, Jung Ho, Ahn, Sung Gyun, Doh, Joon-Hyoung, Shin, Sanghoon, Shim, Jaemin, Her, Ae-Young, Kim, Byung Gyu, Lim, Sang Wook, Kwon, Taek-Geun, Lee, Kyoung-Hoon, Kim, Daehoon, Lee, Yong-Joon, Yu, Hee Tae, Kim, Tae-Hoon, Shin, Dong-Ho, Pak, Hui-Nam, and Kim, Jung-Sun

Abstract

Both anticoagulation and antiplatelet therapies are recommended after percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF). Although contemporary guidelines recommend discontinuation of antiplatelet therapy 1 year after drug-eluting stent (DES) implantation due to excessive bleeding risk, supporting randomized trials are still lacking. The ADAPT AF-DES trial is a multicenter, prospective, open-label, randomized, non-inferiority trial, enrolling 960 patients with AF with a CHA 2 DS 2 -VASc score > 1, who underwent PCI with DES implantation at least 12 months before enrollment. Eligible patients are randomly assigned to receive either non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy or NOAC plus clopidogrel combination therapy. The primary outcome is net adverse clinical event (NACE) at 1 year after randomization, defined as a composite of all-cause death, myocardial infarction, stent thrombosis, stroke, systemic embolism, and major or clinically relevant non-major bleeding, as defined by the International Society on Thrombosis and Hemostasis criteria. We hypothesize that NOAC monotherapy would be non-inferior to NOAC plus clopidogrel combination therapy for NACE in patients with AF beyond 12 months after DES implantation. The ADAPT AF-DES trial will evaluate the efficacy and safety of NOAC monotherapy versus NOAC plus clopidogrel combination therapy in patients with AF beyond 12 months after PCI with DES implantation. The ADAPT AF-DES trial will provide robust evidence for an optimal antithrombotic strategy in patients with AF after DES implantation. https://www.clinicaltrials.gov. Unique identifier: NCT04250116. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Tyrosinase inhibitors isolated from Iris bungei collected in Mongolia.

Author

Jeong, Gyeong Han and Kim, Tae Hoon

Abstract

Iris bungei (Iridaceae) collected in Mongolia was subjected to bioassay-directed isolation using a tyrosinase inhibition assay. A dimeric stilbene (1), two phenylpropanoid glycosides (2 , 3), and a flavone glycoside (5), along with fifteen known secondary metabolites (4 , 6 19) were isolated from the methanolic extract of the whole plant. The structures of the new metabolites were elucidated by 1D and 2D NMR spectroscopic and chemical methods. Among the isolated compounds, the new triferuloyl glycosides (2 and 3) exhibited significant tyrosinase inhibitory effects with IC 50 values of 16.4 ± 0.5 and 18.3 ± 0.7 μM, respectively. [Display omitted] • A dimeric stilbene, two phenylpropanoid glycosides, and a flavone glycoside isolated from Iris bungei. • New structures were elucidated by analysis of spectroscopic and chemical methods. • Two new triferuloyl glycosides exhibited significant tyrosinase inhibitory effects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Tailored treatment modality in acute type A intramural hematoma.

Author

Kim, Myeong Su, Kim, Tae-Hoon, Lee, Ha, Song, Suk-Won, and Yoo, Kyung-Jong

Abstract

Intramural hematoma may be generated by a minimal intimal tear. Most surgeries for acute type A intramural hematoma are performed on the proximal aorta alone regardless of the intimal tear site. Under the assumption that major adverse aortic events (MAAEs) would be related to the location of primary intimal tear, we reviewed preoperative computed tomography scan findings. Sixty patients with acute type A intramural hematoma who underwent surgery from January 2008 to December 2019 were retrospectively analyzed. The maximal diameter, maximal thickness of the intramural hematoma, and hematoma thickness ratio of the ascending and descending aortae were measured. MAAEs were defined as newly developed aortic dissection, rupture, newly developed penetrating aortic ulcer (PAU), enlargement of the PAU, and aortic death. The number of patients with PAU in the descending aorta (dPAU) was significantly higher in the MAAE (+) group. The MAAE (+) group showed lower measurements of the ascending aorta and higher measurements of the descending aorta than the MAAE (–) group. In the univariate analysis, dPAU, hematoma thickness ratio of the ascending and descending aortae, and descending aorta hematoma thickness >8.58 mm were risk factors of MAAE. Intimal tear noted intraoperatively and ascending aorta hematoma thickness >10.25 mm were protective factors of MAAE. Aortopathies (ie, PAU, ulcer-like projections, and the hematoma thickness ratio) are important clues to determine the location of intimal tear. Occurrence of MAAEs seems to be highly related to the pathology of the descending aorta. The modalities of treatment for stable acute type A intramural hematoma that do not meet the existing guidelines should be tailored to the location of the intimal tear. Tailored treatment of acute type A intramural hematoma according to the location of intimal tear. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results